Adverse effects of statins - mechanisms and consequences - PubMed (original) (raw)
Review
Adverse effects of statins - mechanisms and consequences
Jerzy Bełtowski et al. Curr Drug Saf. 2009 Sep.
Abstract
Statins inhibit 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis, which converts HMG-CoA to mevalonate. Statins lower plasma low-density lipoprotein (LDL) cholesterol by causing intracellular cholesterol depletion and upregulating the expression of LDL receptors. Apart from cholesterol, mevalonate is also the substrate for the synthesis of nonsteroid isoprenoids including farnesylpyrophosphate, geranylgeranylpyrophosphate (both attached to small GTP-binding proteins by protein prenyltransferases), coenzyme Q, dolichol, isopentenyladenosine, etc. Depletion of these isoprenoids results in so called "pleiotropic" effects of statins which are independent of cholesterol lowering. Although statins are generally well-tolerated, adverse effects may occur in some patients. These effects result from impaired protein prenylation, deficiency of coenzyme Q involved in mitochondrial electron transport and antioxidant protection, abnormal protein glycosylation due to dolichol shortage, or deficiency of selenoproteins. Myopathy is the most frequent side effect of statins and in some cases may have a form of severe rhabdomyolysis. Less common adverse effects include hepatotoxicity, peripheral neuropathy, impaired myocardial contractility and autoimmune diseases. The risk of these unfavorable effects is largely outweighed by great reduction of cardiovascular events in statin users. However, due to increasing number of patients taking statins, monitoring for any side effects, intense research to recognize their mechanisms and to identify susceptible patients, as well as rational management of these complications are mandatory to further improve safety of these excellent drugs.
Similar articles
- Are statins really wonder drugs?
Grover HS, Luthra S, Maroo S. Grover HS, et al. J Formos Med Assoc. 2014 Dec;113(12):892-8. doi: 10.1016/j.jfma.2013.05.016. Epub 2013 Nov 11. J Formos Med Assoc. 2014. PMID: 24231094 Review. - Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Danesh FR, Kanwar YS. Danesh FR, et al. FASEB J. 2004 May;18(7):805-15. doi: 10.1096/fj.03-0839rev. FASEB J. 2004. PMID: 15117885 Review. - Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
Sivashanmugarajah A, Fulcher J, Sullivan D, Elam M, Jenkins A, Keech A. Sivashanmugarajah A, et al. Intern Med J. 2019 Sep;49(9):1081-1091. doi: 10.1111/imj.14429. Intern Med J. 2019. PMID: 31507054 Review. - Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
Evans M, Rees A. Evans M, et al. Drug Saf. 2002;25(9):649-63. doi: 10.2165/00002018-200225090-00004. Drug Saf. 2002. PMID: 12137559 Review. - Coenzyme Q(10) and statin myalgia: what is the evidence?
Mas E, Mori TA. Mas E, et al. Curr Atheroscler Rep. 2010 Nov;12(6):407-13. doi: 10.1007/s11883-010-0134-3. Curr Atheroscler Rep. 2010. PMID: 20725809
Cited by
- An investigation on the cardioprotective potential of lichen compound protocetraric acid by H2O2-induced toxicity in H9c2 rat heart cells through in vitro and in silico analysis.
Sutar RR, Mapari SV, Gaikwad SB, Khare R, Behera BC. Sutar RR, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug 22. doi: 10.1007/s00210-024-03390-3. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39172149 - Acute sleep deprivation-induced hepatotoxicity and dyslipidemia in middle-aged female rats and its amelioration by butanol extract of Tinospora cordifolia.
Bajaj P, Kaur T, Singh AP, Kaur G. Bajaj P, et al. Lab Anim Res. 2024 Aug 21;40(1):29. doi: 10.1186/s42826-024-00216-4. Lab Anim Res. 2024. PMID: 39164744 Free PMC article. - Time-Restricted Feeding Reduces Atherosclerosis in LDLR KO Mice but Not in ApoE Knockout Mice.
Chaix A, Lin T, Ramms B, Cutler RG, Le T, Lopez C, Miu P, Pinto AFM, Saghatelian A, Playford MP, Mehta NN, Mattson MP, Gordts P, Witztum JL, Panda S. Chaix A, et al. Arterioscler Thromb Vasc Biol. 2024 Sep;44(9):2069-2087. doi: 10.1161/ATVBAHA.124.320998. Epub 2024 Aug 1. Arterioscler Thromb Vasc Biol. 2024. PMID: 39087348 - Potentials of Natural Antioxidants in Reducing Inflammation and Oxidative Stress in Chronic Kidney Disease.
Lee OYA, Wong ANN, Ho CY, Tse KW, Chan AZ, Leung GP, Kwan YW, Yeung MHY. Lee OYA, et al. Antioxidants (Basel). 2024 Jun 20;13(6):751. doi: 10.3390/antiox13060751. Antioxidants (Basel). 2024. PMID: 38929190 Free PMC article. Review. - Effect of pitavastatin on erythrocyte membrane fatty acid content in patients with chronic kidney disease: two-arm parallel randomized controlled trial.
Kim M, Kim SE, Lee SM, An WS. Kim M, et al. J Yeungnam Med Sci. 2024 Jul;41(3):188-195. doi: 10.12701/jyms.2024.00094. Epub 2024 May 8. J Yeungnam Med Sci. 2024. PMID: 38715530 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical